Follow
Craig Gedye
Craig Gedye
Conjoint Associate Professor, Hunter Medical Research Institute
Verified email at newcastle.edu.au
Title
Cited by
Cited by
Year
An immune atlas of clear cell renal cell carcinoma
S Chevrier, JH Levine, VRT Zanotelli, K Silina, D Schulz, M Bacac, ...
Cell 169 (4), 736-749. e18, 2017
9072017
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
6592021
Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide
AJ Kettle, CA GEDYE, CC WINTERBOURN
Biochemical Journal 321 (2), 503-508, 1997
2741997
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
JM Stewart, PA Shaw, C Gedye, MQ Bernardini, BG Neel, LE Ailles
Proceedings of the National Academy of Sciences 108 (16), 6468-6473, 2011
2592011
The regulatory T cell–associated transcription factor FoxP3 is expressed by tumor cells
LM Ebert, BS Tan, J Browning, S Svobodova, SE Russell, N Kirkpatrick, ...
Cancer research 68 (8), 3001-3009, 2008
2442008
Inhibition of myeloperoxidase by benzoic acid hydrazides
AJ Kettle, CA Gedye, MB Hampton, CC Winterbourn
Biochemical Journal 308 (2), 559-563, 1995
2081995
Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response …
L Emmett, M Crumbaker, B Ho, K Willowson, P Eu, L Ratnayake, ...
Clinical genitourinary cancer 17 (1), 15-22, 2019
1652019
Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the …
CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ...
European urology 76 (1), 73-81, 2019
1352019
Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial
P Grimison, A Mersiades, A Kirby, N Lintzeris, R Morton, P Haber, I Olver, ...
Annals of Oncology 31 (11), 1553-1560, 2020
1202020
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP …
JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ...
The Lancet Oncology 23 (11), 1389-1397, 2022
1092022
Superoxide is an antagonist of anti-inflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase
AJ Kettle, CA Gedye, CC Winterbourn
Biochemical pharmacology 45 (10), 2003-2010, 1993
1081993
Infectious complications of biological and small molecule targeted immunomodulatory therapies
JS Davis, D Ferreira, E Paige, C Gedye, M Boyle
Clinical microbiology reviews 33 (3), 10.1128/cmr. 00035-19, 2020
1042020
TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic …
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
Lancet 397 (10276), 797-804, 2021
852021
Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity
CA Gedye, A Hussain, J Paterson, A Smrke, H Saini, D Sirskyj, K Pereira, ...
PloS one 9 (8), e105602, 2014
812014
TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC …
MS Hofman, L Emmett, SK Sandhu, A Iravani, AM Joshua, JC Goh, ...
Journal of Clinical Oncology 38 (15_suppl), 5500-5500, 2020
792020
Predicting clinical outcome through molecular profiling in stage III melanoma
T John, MA Black, TT Toro, D Leader, CA Gedye, ID Davis, PJ Guilford, ...
Clinical Cancer Research 14 (16), 5173-5180, 2008
782008
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells
C Gedye, J Quirk, J Browning, S Svobodová, T John, P Sluka, PR Dunbar, ...
Cancer immunology, immunotherapy 58, 1635-1646, 2009
772009
Human perforin mutations and susceptibility to multiple primary cancers
JA Trapani, KYT Thia, M Andrews, ID Davis, C Gedye, P Parente, ...
Oncoimmunology 2 (4), e24185, 2013
712013
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
L Khoja, M Kibiro, UR Metser, C Gedye, D Hogg, MO Butler, EG Atenafu, ...
British Journal of Cancer 115 (10), 1186-1192, 2016
642016
Targeting the TSH receptor in thyroid cancer
CW Rowe, JW Paul, C Gedye, JM Tolosa, C Bendinelli, S McGrath, ...
Endocrine-Related Cancer 24 (6), R191-R202, 2017
632017
The system can't perform the operation now. Try again later.
Articles 1–20